PACB
Pacific Biosciences of California, Inc.
Price Chart
Latest Quote
$1.32
-0.08 (-5.71%)
Current Price
| Previous Close | $1.40 |
| Open | $1.39 |
| Day High | $1.41 |
| Day Low | $1.32 |
| Volume | 4,483,199 |
Stock Information
| Shares Outstanding | 310.60M |
| Total Debt | $706.39M |
| Cash Equivalents | $275.96M |
| Revenue | $160.03M |
| Net Income | $-128.58M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $409.99M |
| EPS (TTM) | $-0.41 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $840.42M |
| Sales | $160.03M |
| Income | $-128.58M |
| Book/sh | $0.01 |
| Cash/sh | $0.89 |
| Employees | 485 |
Financial Ratios
| Quick Ratio | 4.67 |
| Current Ratio | 5.65 |
| Debt/Eq | 29855.79 |
Returns & Margins
| ROA | -11.96% |
| ROE | -273.55% |
| Gross Margin | 38.33% |
| Operating Margin | -102.89% |
| Profit Margin | -80.34% |
Ownership
| Insider Ownership | 8.77% |
| Institutional Ownership | 54.02% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.33 |
| P/S | 2.56 |
| P/B | 165.00 |
Analyst Data
| Recommendation | none |
| Target Price | $2.46 |
Technical Indicators
| SMA20 | $1.40 |
| SMA50 | $1.45 |
| SMA200 | $1.68 |
| RSI | 26.79 |
| ATR | 0.1143 |
| Shares Float | 303.44M |
| Short Float | 18.03% |
| Short Ratio | 7.88 |
| Volatility | 2.32 |
| Rel Volume | 0.80 |
Performance History
| Week | +0.76% |
| Month | +10.92% |
| Quarter | -0.75% |
| 6 Months | -31.61% |
| YTD | -28.26% |
| Year | +0.76% |
| 3 Years | -89.99% |
| 5 Years | -95.53% |
| 10 Years | -84.65% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $1.32 | 4,544,000 |
| 2026-06-18 | $1.40 | 4,318,200 |
| 2026-06-17 | $1.34 | 4,798,100 |
| 2026-06-16 | $1.35 | 3,742,800 |
| 2026-06-15 | $1.32 | 5,298,200 |
| 2026-06-12 | $1.31 | 4,976,300 |
| 2026-06-11 | $1.35 | 5,069,300 |
| 2026-06-10 | $1.37 | 5,224,300 |
| 2026-06-09 | $1.37 | 3,834,100 |
| 2026-06-08 | $1.38 | 4,225,700 |
| 2026-06-05 | $1.45 | 6,483,700 |
| 2026-06-04 | $1.63 | 7,876,100 |
| 2026-06-03 | $1.58 | 6,842,400 |
| 2026-06-02 | $1.58 | 7,936,300 |
| 2026-06-01 | $1.58 | 8,207,800 |
| 2026-05-29 | $1.49 | 7,009,900 |
| 2026-05-28 | $1.47 | 9,354,400 |
| 2026-05-27 | $1.29 | 3,472,700 |
| 2026-05-26 | $1.26 | 6,286,900 |
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
đ° Latest News
Is Pacific Biosciences of California, Inc. (PACB) One of the Best Genomics Stocks to Buy According to Wall Street?
Insider Monkey âĸ 2026-06-16T12:53:25Z
Cathie Wood Buys $444 Million in SpaceX, Dumps Tesla and AMD
GuruFocus.com âĸ 2026-06-15T18:48:08Z3 Unprofitable Stocks That Concern Us
StockStory âĸ 2026-06-15T13:00:07Z
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
Zacks âĸ 2026-06-12T22:15:02Z
How The Pacific Biosciences (PACB) Investment Narrative Is Evolving Without New Analyst Targets
Simply Wall St. âĸ 2026-06-07T05:11:15Z
Here's Why You Should Add PacBio Stock to Your Portfolio Now
Zacks âĸ 2026-06-03T17:43:00Z
Q1 Earnings Highs And Lows: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks
StockStory âĸ 2026-06-02T18:21:23Z
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Zacks âĸ 2026-06-02T16:09:00Z
3 Russell 2000 Stocks Walking a Fine Line
StockStory âĸ 2026-05-29T20:24:38Z
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology
Zacks âĸ 2026-05-20T15:15:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $92,354,000 | $81,387,000 | $127,364,000 | $61,951,000 |
| Cost Of Revenue | $114,225,000 | $116,732,000 | $147,741,000 | $79,269,000 |
| Total Revenue | $160,005,000 | $154,014,000 | $200,521,000 | $128,304,000 |
| Operating Revenue | $160,005,000 | $154,014,000 | $200,521,000 | $128,304,000 |
| Expenses | ||||
| Interest Expense | $6,954,000 | $13,412,000 | $14,343,000 | $14,690,000 |
| Total Expenses | $717,566,000 | $444,677,000 | $510,886,000 | $433,123,000 |
| Other Income Expense | $18,457,000 | $-5,460,000 | $6,549,000 | $5,261,000 |
| Other Non Operating Income Expenses | $14,757,000 | $23,783,000 | $32,684,000 | $7,638,000 |
| Net Non Operating Interest Income Expense | $-6,954,000 | $-13,412,000 | $-14,343,000 | $-14,690,000 |
| Interest Expense Non Operating | $6,954,000 | $13,412,000 | $14,343,000 | $14,690,000 |
| Operating Expense | $603,341,000 | $327,945,000 | $363,145,000 | $353,854,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-546,376,000 | $-309,851,000 | $-306,735,000 | $-314,248,000 |
| Net Interest Income | $-6,954,000 | $-13,412,000 | $-14,343,000 | $-14,690,000 |
| Normalized Income | $-549,299,000 | $-286,749,030 | $-281,540,860 | $-311,873,377 |
| Net Income From Continuing And Discontinued Operation | $-546,376,000 | $-309,851,000 | $-306,735,000 | $-314,248,000 |
| Total Operating Income As Reported | $-553,861,000 | $-474,313,000 | $-334,467,000 | $-307,196,000 |
| Net Income Common Stockholders | $-546,376,000 | $-309,851,000 | $-306,735,000 | $-314,248,000 |
| Net Income | $-546,376,000 | $-309,851,000 | $-306,735,000 | $-314,248,000 |
| Net Income Including Noncontrolling Interests | $-546,376,000 | $-309,851,000 | $-306,735,000 | $-314,248,000 |
| Net Income Continuous Operations | $-546,376,000 | $-309,851,000 | $-306,735,000 | $-314,248,000 |
| Pretax Income | $-546,058,000 | $-309,535,000 | $-318,159,000 | $-314,248,000 |
| Special Income Charges | $3,700,000 | $-29,243,000 | $-26,135,000 | $-2,377,000 |
| Operating Income | $-557,561,000 | $-290,663,000 | $-310,365,000 | $-304,819,000 |
| Depreciation Amortization Depletion Income Statement | $364,541,000 | $18,006,000 | $6,157,000 | $0 |
| Depreciation And Amortization In Income Statement | $364,541,000 | $18,006,000 | $6,157,000 | $0 |
| Amortization Of Intangibles Income Statement | $364,541,000 | $18,006,000 | $6,157,000 | $0 |
| Gross Profit | $45,780,000 | $37,282,000 | $52,780,000 | $49,035,000 |
| Per Share | ||||
| Diluted EPS | $-1.82 | $-1.58 | $-1.21 | $-1.40 |
| Basic EPS | $-1.82 | $-1.12 | $-1.21 | $-1.40 |
| Other | ||||
| Tax Effect Of Unusual Items | $777,000 | $-6,141,030 | $-940,860 | $-2,377 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-156,392,000 | $-213,529,000 | $-251,147,000 | $-279,863,000 |
| Total Unusual Items | $3,700,000 | $-29,243,000 | $-26,135,000 | $-2,377,000 |
| Total Unusual Items Excluding Goodwill | $3,700,000 | $-29,243,000 | $-26,135,000 | $-2,377,000 |
| Reconciled Depreciation | $386,412,000 | $53,351,000 | $26,534,000 | $17,318,000 |
| EBITDA (Bullshit earnings) | $-152,692,000 | $-242,772,000 | $-277,282,000 | $-282,240,000 |
| EBIT | $-539,104,000 | $-296,123,000 | $-303,816,000 | $-299,558,000 |
| Diluted Average Shares | $299,959,000 | $288,366,000 | $253,629,000 | $224,550,000 |
| Basic Average Shares | $299,959,000 | $274,488,000 | $253,629,000 | $224,550,000 |
| Diluted NI Availto Com Stockholders | $-546,376,000 | $-309,851,000 | $-306,735,000 | $-314,248,000 |
| Tax Provision | $318,000 | $316,000 | $-11,424,000 | $0 |
| Write Off | $15,000,000 | $184,500,000 | $0 | $0 |
| Restructuring And Mergern Acquisition | $-18,700,000 | $-850,000 | $24,102,000 | $2,377,000 |
| Amortization | $364,541,000 | $18,006,000 | $6,157,000 | $0 |
| Research And Development | $97,307,000 | $134,922,000 | $187,170,000 | $193,000,000 |
| Selling General And Administration | $141,493,000 | $175,017,000 | $169,818,000 | $160,854,000 |
| Other Special Charges | - | $-154,407,000 | $2,033,000 | - |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-327,536,000 | $-200,739,000 | $-217,941,000 | $-257,315,000 |
| Total Assets | $784,083,000 | $1,260,447,000 | $1,746,013,000 | $1,767,086,000 |
| Total Non Current Assets | $409,031,000 | $764,766,000 | $1,003,966,000 | $915,012,000 |
| Other Non Current Assets | $10,305,000 | $10,837,000 | $15,696,000 | $13,450,000 |
| Goodwill And Other Intangible Assets | $332,885,000 | $707,333,000 | $919,245,000 | $820,219,000 |
| Other Intangible Assets | $15,124,000 | $389,572,000 | $456,984,000 | $410,245,000 |
| Current Assets | $375,052,000 | $495,681,000 | $742,047,000 | $852,074,000 |
| Other Current Assets | $10,793,000 | $18,781,000 | $17,040,000 | $10,289,000 |
| Restricted Cash | $20,000 | $690,000 | $300,000 | $300,000 |
| Inventory | $49,285,000 | $58,755,000 | $56,676,000 | $50,381,000 |
| Receivables | $35,448,000 | $27,524,000 | $36,615,000 | $18,786,000 |
| Accounts Receivable | $35,448,000 | $27,524,000 | $36,615,000 | $18,786,000 |
| Cash Cash Equivalents And Short Term Investments | $279,506,000 | $389,931,000 | $631,416,000 | $772,318,000 |
| Cash And Cash Equivalents | $63,707,000 | $55,370,000 | $179,911,000 | $325,089,000 |
| Cash Equivalents | $3,211,000 | $0 | $109,739,000 | $187,453,000 |
| Cash Financial | $60,496,000 | $55,370,000 | $70,172,000 | $137,636,000 |
| Prepaid Assets | - | - | - | $10,289,000 |
| Debt | ||||
| Net Debt | $581,675,000 | $592,124,000 | $712,822,000 | $573,436,000 |
| Total Debt | $702,422,000 | $672,434,000 | $933,930,000 | $948,481,000 |
| Long Term Debt And Capital Lease Obligation | $701,974,000 | $662,408,000 | $923,849,000 | $937,753,000 |
| Long Term Debt | $645,382,000 | $647,494,000 | $892,243,000 | $896,683,000 |
| Current Debt And Capital Lease Obligation | $448,000 | $10,026,000 | $10,081,000 | $10,728,000 |
| Current Debt | - | - | $490,000 | $1,842,000 |
| Other Current Borrowings | - | - | $490,000 | $1,842,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $778,734,000 | $753,853,000 | $1,044,709,000 | $1,204,182,000 |
| Total Non Current Liabilities Net Minority Interest | $705,903,000 | $687,554,000 | $949,680,000 | $940,847,000 |
| Non Current Deferred Liabilities | $3,929,000 | $5,900,000 | $5,530,000 | $1,794,000 |
| Current Liabilities | $72,831,000 | $66,299,000 | $95,029,000 | $263,335,000 |
| Other Current Liabilities | $654,000 | $1,210,000 | $4,121,000 | $173,847,000 |
| Current Deferred Liabilities | $15,936,000 | $13,864,000 | $16,342,000 | $30,498,000 |
| Payables And Accrued Expenses | $54,416,000 | $39,185,000 | $60,770,000 | $44,624,000 |
| Interest Payable | $3,270,000 | $2,470,000 | $2,834,000 | $5,100,000 |
| Payables | $20,770,000 | $16,590,000 | $15,062,000 | $12,028,000 |
| Accounts Payable | $20,770,000 | $16,590,000 | $15,062,000 | $12,028,000 |
| Other Non Current Liabilities | - | $19,246,000 | $20,301,000 | $1,300,000 |
| Equity | ||||
| Common Stock Equity | $5,349,000 | $506,594,000 | $701,304,000 | $562,904,000 |
| Total Equity Gross Minority Interest | $5,349,000 | $506,594,000 | $701,304,000 | $562,904,000 |
| Stockholders Equity | $5,349,000 | $506,594,000 | $701,304,000 | $562,904,000 |
| Gains Losses Not Affecting Retained Earnings | $457,000 | $422,000 | $219,000 | $-4,765,000 |
| Other Equity Adjustments | $457,000 | $422,000 | $219,000 | $-4,765,000 |
| Retained Earnings | $-2,695,302,000 | $-2,148,926,000 | $-1,839,075,000 | $-1,532,340,000 |
| Other | ||||
| Ordinary Shares Number | $301,956,000 | $294,418,000 | $267,744,000 | $226,505,000 |
| Share Issued | $301,956,000 | $294,418,000 | $267,744,000 | $226,505,000 |
| Tangible Book Value | $-327,536,000 | $-200,739,000 | $-217,941,000 | $-257,315,000 |
| Invested Capital | $650,731,000 | $1,154,088,000 | $1,594,037,000 | $1,461,429,000 |
| Working Capital | $302,221,000 | $429,382,000 | $647,018,000 | $588,739,000 |
| Capital Lease Obligations | $57,040,000 | $24,940,000 | $41,197,000 | $49,956,000 |
| Total Capitalization | $650,731,000 | $1,154,088,000 | $1,593,547,000 | $1,459,587,000 |
| Additional Paid In Capital | $2,699,892,000 | $2,654,804,000 | $2,539,892,000 | $2,099,782,000 |
| Capital Stock | $302,000 | $294,000 | $268,000 | $227,000 |
| Common Stock | $302,000 | $294,000 | $268,000 | $227,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $3,929,000 | $5,900,000 | $5,530,000 | $1,794,000 |
| Long Term Capital Lease Obligation | $56,592,000 | $14,914,000 | $31,606,000 | $41,070,000 |
| Current Deferred Revenue | $15,936,000 | $13,864,000 | $16,342,000 | $30,498,000 |
| Current Capital Lease Obligation | $448,000 | $10,026,000 | $9,591,000 | $8,886,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,377,000 | $2,014,000 | $3,715,000 | $3,638,000 |
| Current Accrued Expenses | $33,646,000 | $22,595,000 | $45,708,000 | $32,596,000 |
| Goodwill | $317,761,000 | $317,761,000 | $462,261,000 | $409,974,000 |
| Net PPE | $65,841,000 | $46,596,000 | $69,025,000 | $81,343,000 |
| Accumulated Depreciation | $-92,470,000 | $-81,948,000 | $-74,794,000 | $-64,988,000 |
| Gross PPE | $158,311,000 | $128,544,000 | $143,819,000 | $146,331,000 |
| Leases | $33,837,000 | $33,770,000 | $35,226,000 | $34,129,000 |
| Construction In Progress | $5,409,000 | $2,276,000 | $1,343,000 | $4,698,000 |
| Other Properties | $41,695,000 | $16,091,000 | $32,593,000 | $39,763,000 |
| Machinery Furniture Equipment | $77,370,000 | $76,407,000 | $74,657,000 | $67,741,000 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-32,113,000 | $-22,768,000 | $-19,157,000 | - |
| Finished Goods | $15,709,000 | $14,081,000 | $15,746,000 | $12,180,000 |
| Work In Process | $27,051,000 | $22,172,000 | $27,653,000 | $14,062,000 |
| Raw Materials | $38,638,000 | $45,270,000 | $32,434,000 | $24,139,000 |
| Other Short Term Investments | $215,799,000 | $334,561,000 | $451,505,000 | $447,229,000 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-118,923,000 | $-212,246,000 | $-268,016,000 | $-280,140,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-111,209,000 | $-206,058,000 | $-259,173,000 | $-263,211,000 |
| Cash Flow From Continuing Operating Activities | $-111,209,000 | $-206,058,000 | $-259,173,000 | $-263,211,000 |
| Operating Gains Losses | - | - | $2,033,000 | $278,000 |
| Investing Activities | ||||
| Capital Expenditure | $-7,714,000 | $-6,188,000 | $-8,843,000 | $-16,929,000 |
| Investing Cash Flow | $115,448,000 | $124,004,000 | $4,604,000 | $116,083,000 |
| Cash Flow From Continuing Investing Activities | $115,448,000 | $124,004,000 | $4,604,000 | $116,083,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $189,200,000 | $0 |
| Financing Cash Flow | $3,428,000 | $-42,987,000 | $108,891,000 | $9,622,000 |
| Cash Flow From Continuing Financing Activities | $3,428,000 | $-42,987,000 | $108,891,000 | $9,622,000 |
| Net Common Stock Issuance | $0 | $0 | $189,200,000 | $0 |
| Common Stock Issuance | $0 | $0 | $189,200,000 | $0 |
| Net Other Financing Charges | - | $-50,200,000 | $-93,786,000 | - |
| Other | ||||
| Repayment Of Debt | $0 | $-490,000 | $-1,842,000 | $-1,608,000 |
| Interest Paid Supplemental Data | $8,264,000 | $14,805,000 | $15,687,000 | $14,049,000 |
| End Cash Position | $65,259,000 | $57,592,000 | $182,633,000 | $325,089,000 |
| Beginning Cash Position | $57,592,000 | $182,633,000 | $328,311,000 | $465,817,000 |
| Changes In Cash | $7,667,000 | $-125,041,000 | $-145,678,000 | $-137,506,000 |
| Proceeds From Stock Option Exercised | $3,428,000 | $7,703,000 | $15,319,000 | $11,230,000 |
| Net Issuance Payments Of Debt | $0 | $-490,000 | $-1,842,000 | $-1,608,000 |
| Net Long Term Debt Issuance | $0 | $-490,000 | $-1,842,000 | $-1,608,000 |
| Long Term Debt Payments | $0 | $-490,000 | $-1,842,000 | $-1,608,000 |
| Net Investment Purchase And Sale | $123,162,000 | $130,192,000 | $13,549,000 | $133,012,000 |
| Sale Of Investment | $340,073,000 | $628,827,000 | $770,116,000 | $575,800,000 |
| Purchase Of Investment | $-216,911,000 | $-498,635,000 | $-756,567,000 | $-442,788,000 |
| Net Business Purchase And Sale | $0 | $0 | $-102,000 | $0 |
| Purchase Of Business | $0 | $0 | $-102,000 | $0 |
| Net Intangibles Purchase And Sale | $-5,000,000 | $0 | $0 | $-179,000 |
| Purchase Of Intangibles | $-5,000,000 | $0 | $0 | $-179,000 |
| Net PPE Purchase And Sale | $-2,714,000 | $-6,188,000 | $-8,843,000 | $-16,750,000 |
| Purchase Of PPE | $-2,714,000 | $-6,188,000 | $-8,843,000 | $-16,750,000 |
| Change In Working Capital | $4,442,000 | $-40,578,000 | $-58,957,000 | $-53,972,000 |
| Change In Other Working Capital | $101,000 | $-2,108,000 | $-10,420,000 | $-3,734,000 |
| Change In Other Current Liabilities | $-470,000 | $-16,532,000 | $-21,192,000 | $-6,837,000 |
| Change In Payables And Accrued Expense | $5,640,000 | $-24,937,000 | $13,309,000 | $-2,626,000 |
| Change In Accrued Expense | $3,158,000 | $-26,342,000 | $13,103,000 | $-3,651,000 |
| Change In Payable | $2,482,000 | $1,405,000 | $206,000 | $1,025,000 |
| Change In Account Payable | $2,482,000 | $1,405,000 | $206,000 | $1,025,000 |
| Change In Prepaid Assets | $8,514,000 | $2,228,000 | $-8,984,000 | $-12,324,000 |
| Change In Inventory | $-1,419,000 | $-8,320,000 | $-13,841,000 | $-33,906,000 |
| Change In Receivables | $-7,924,000 | $9,091,000 | $-17,829,000 | $5,455,000 |
| Changes In Account Receivables | $-7,924,000 | $9,091,000 | $-17,829,000 | $5,455,000 |
| Other Non Cash Items | $-17,012,000 | $-155,885,000 | $19,514,000 | $3,295,000 |
| Stock Based Compensation | $41,668,000 | $71,036,000 | $72,118,000 | $78,613,000 |
| Provisionand Write Offof Assets | $9,568,000 | $4,618,000 | $10,584,000 | $6,027,000 |
| Asset Impairment Charge | $15,000,000 | $184,500,000 | $0 | $0 |
| Amortization Of Securities | $-4,365,000 | $-13,044,000 | $-12,840,000 | $-244,000 |
| Deferred Tax | $-546,000 | $-205,000 | $-11,424,000 | $0 |
| Deferred Income Tax | $-546,000 | $-205,000 | $-11,424,000 | $0 |
| Depreciation Amortization Depletion | $386,412,000 | $53,351,000 | $26,534,000 | $17,318,000 |
| Depreciation And Amortization | $386,412,000 | $53,351,000 | $26,534,000 | $17,318,000 |
| Amortization Cash Flow | $369,448,000 | $27,412,000 | $8,261,000 | $913,000 |
| Amortization Of Intangibles | $369,448,000 | $27,412,000 | $8,261,000 | $913,000 |
| Depreciation | $16,964,000 | $25,939,000 | $18,273,000 | $16,405,000 |
| Net Income From Continuing Operations | $-546,376,000 | $-309,851,000 | $-306,735,000 | $-314,248,000 |
| Other Cash Adjustment Outside Changein Cash | - | $-2,222,000 | $-2,722,000 | $-3,222,000 |
| Issuance Of Debt | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
| Gain Loss On Sale Of PPE | - | - | - | $278,000 |
Fetched: 2026-06-16